Detalles de la búsqueda
1.
Whole-genome sequencing predicting phenotypic antitubercular drug resistance: meta-analysis.
J Infect Dis
; 2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37946558
2.
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
Cochrane Database Syst Rev
; 6: CD012066, 2023 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37276335
3.
Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Int Arch Allergy Immunol
; 182(8): 744-756, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887721
4.
Atezolizumab for PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 384(6): 583-584, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33567200
5.
Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer.
Thorac Cancer
; 15(15): 1208-1217, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38602166
6.
Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan.
Sci Rep
; 13(1): 5208, 2023 03 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36997606
7.
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes.
Cancers (Basel)
; 15(21)2023 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37958421
8.
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Ther Adv Med Oncol
; 15: 17588359231198453, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37720498
9.
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis.
Thorac Cancer
; 13(1): 84-94, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34791815
10.
Adverse events induced by nivolumab and ipilimumab combination regimens.
Ther Adv Med Oncol
; 14: 17588359211058393, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35173819
11.
Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.
Transl Lung Cancer Res
; 11(7): 1420-1433, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958331
12.
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.
Thorac Cancer
; 13(2): 228-235, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34866339
13.
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1-49%: a network meta-analysis.
Transl Lung Cancer Res
; 10(8): 3550-3566, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34584856
14.
Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia.
Can Respir J
; 2021: 5644824, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34824650
15.
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients: A meta-analysis.
Thorac Cancer
; 12(7): 1096-1105, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565276
16.
T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Thorac Cancer
; 12(11): 1726-1734, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33943031
17.
Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs.
Brain Res
; 1602: 62-74, 2015 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25601010
Resultados
1 -
17
de 17
1
Próxima >
>>